25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Bone Biologics Corp
Buy, Hold or Sell?

Let's analyze Bone Biologics Corp together

I guess you are interested in Bone Biologics Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Bone Biologics Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Bone Biologics Corp

I send you an email if I find something interesting about Bone Biologics Corp.

1. Quick Overview

1.1. Quick analysis of Bone Biologics Corp (30 sec.)










1.2. What can you expect buying and holding a share of Bone Biologics Corp? (30 sec.)

How much money do you get?

How much money do you get?
$1.53
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$1.81
Expected worth in 1 year
$1.81
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$1.53
Return On Investment
127.7%

For what price can you sell your share?

Current Price per Share
$1.20
Expected price per share
$0.8 - $1.45
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Bone Biologics Corp (5 min.)




Live pricePrice per Share (EOD)
$1.20
Intrinsic Value Per Share
$-25.43 - $-20.28
Total Value Per Share
$-23.62 - $-18.48

2.2. Growth of Bone Biologics Corp (5 min.)




Is Bone Biologics Corp growing?

Current yearPrevious yearGrowGrow %
How rich?$3.7m$4.5m-$1.2m-37.1%

How much money is Bone Biologics Corp making?

Current yearPrevious yearGrowGrow %
Making money-$1.8m-$1.2m-$616k-33.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Bone Biologics Corp (5 min.)




2.4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#260 / 320

Most Revenue
#313 / 320

Most Profit
#174 / 320

Most Efficient
#116 / 320
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Bone Biologics Corp?

Welcome investor! Bone Biologics Corp's management wants to use your money to grow the business. In return you get a share of Bone Biologics Corp.

First you should know what it really means to hold a share of Bone Biologics Corp. And how you can make/lose money.

Speculation

The Price per Share of Bone Biologics Corp is $1.2. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bone Biologics Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bone Biologics Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.81. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.38 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bone Biologics Corp.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.98-165.1%-0.88-73.1%-0.86-71.8%-0.45-37.5%-0.80-66.6%
Usd Book Value Change Per Share0.4235.1%0.000.0%-0.07-6.0%0.3630.2%0.053.8%
Usd Dividend Per Share1.53127.7%0.3831.9%0.000.0%0.086.4%0.043.2%
Usd Total Gains Per Share1.95162.8%0.3831.9%-0.07-6.0%0.4436.5%0.087.0%
Usd Price Per Share2.13-2.50-0.65-1.27-1.14-
Price to Earnings Ratio-0.27--0.98--0.19--1.46--0.77-
Price-to-Total Gains Ratio1.09--1.78-0.09--2.65--1.64-
Price to Book Ratio1.18-1.63-0.30-0.61-0.12-
Price-to-Total Gains Ratio1.09--1.78-0.09--2.65--1.64-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.2
Number of shares833
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.380.08
Usd Book Value Change Per Share0.000.36
Usd Total Gains Per Share0.380.44
Gains per Quarter (833 shares)319.00365.24
Gains per Year (833 shares)1,276.001,460.97
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11276-0126625512061451
22553-1254251124112912
33829-1381876636174373
45105-15094102148235834
56381-16370127660297295
67658-27646153272348756
78934-289221787844010217
810210-2101982042964611678
911486-21147422971085113139
1012763-31275025531205714600

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%1.042.00.02.3%
Book Value Change Per Share2.02.00.050.0%6.06.00.050.0%7.013.00.035.0%13.027.00.032.5%14.029.00.032.6%
Dividend per Share1.00.03.025.0%1.00.011.08.3%1.00.019.05.0%1.00.039.02.5%1.00.042.02.3%
Total Gains per Share2.02.00.050.0%6.06.00.050.0%7.013.00.035.0%13.027.00.032.5%14.029.00.032.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Bone Biologics Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4210.000+100%-0.073+117%0.362+16%0.045+831%
Book Value Per Share--1.8091.584+14%2.171-17%-0.191+111%-1.640+191%
Current Ratio--14.87113.479+10%3.295+351%16.578-10%12.616+18%
Debt To Asset Ratio--0.0670.105-36%0.346-81%1373.110-100%692.030-100%
Debt To Equity Ratio--0.0720.125-42%0.632-89%0.162-56%0.081-11%
Dividend Per Share--1.5320.383+300%-+100%0.077+1900%0.038+3900%
Enterprise Value--7759080.2007891540.000-2%5245794.986+48%7764816.7650%4488086.956+73%
Eps---1.981-0.877-56%-0.862-56%-0.450-77%-0.800-60%
Ev To Ebitda Ratio---2.040-2.334+14%0.055-3825%-3.379+66%inf+inf%
Ev To Sales Ratio--infinfnan%infnan%nannan%nannan%
Free Cash Flow Per Share---0.273-0.571+109%-1.131+315%-0.410+50%-0.455+67%
Free Cash Flow To Equity Per Share--0.589-0.106+118%0.459+28%0.298+98%0.172+242%
Gross Profit Margin--1.0001.0000%1.0000%1.025-2%1.013-1%
Intrinsic Value_10Y_max---20.285--------
Intrinsic Value_10Y_min---25.430--------
Intrinsic Value_1Y_max---1.853--------
Intrinsic Value_1Y_min---2.533--------
Intrinsic Value_3Y_max---5.704--------
Intrinsic Value_3Y_min---7.670--------
Intrinsic Value_5Y_max---9.721--------
Intrinsic Value_5Y_min---12.830--------
Market Cap2516088.000-78%4466056.2005241850.000-15%1367231.736+227%3236256.197+38%2771155.253+61%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.663-78%1.1781.633-28%0.297+296%0.610+93%0.124+849%
Pe Ratio-0.151+44%-0.269-0.976+263%-0.189-30%-1.464+444%-0.767+185%
Price Per Share1.200-78%2.1302.500-15%0.652+227%1.268+68%1.137+87%
Price To Free Cash Flow Ratio-1.099+44%-1.951-1.174-40%-0.127-93%-1.763-10%-1.155-41%
Price To Total Gains Ratio0.614-78%1.090-1.782+263%0.089+1123%-2.653+343%-1.644+251%
Quick Ratio--13.04511.720+11%3.031+330%15.765-17%10.938+19%
Return On Assets---1.022-0.477-53%-0.221-78%-46.107+4413%-67.244+6482%
Return On Equity---1.095-0.533-51%-0.460-58%-0.224-80%-0.112-90%
Total Gains Per Share--1.9530.383+410%-0.073+104%0.438+346%0.084+2238%
Usd Book Value--3792416.0003320670.500+14%4551402.000-17%-2610928.850+169%-4639423.004+222%
Usd Book Value Change Per Share--0.4210.000+100%-0.073+117%0.362+16%0.045+831%
Usd Book Value Per Share--1.8091.584+14%2.171-17%-0.191+111%-1.640+191%
Usd Dividend Per Share--1.5320.383+300%-+100%0.077+1900%0.038+3900%
Usd Eps---1.981-0.877-56%-0.862-56%-0.450-77%-0.800-60%
Usd Free Cash Flow---572162.000-1197363.250+109%-2372170.000+315%-893467.900+56%-981465.856+72%
Usd Free Cash Flow Per Share---0.273-0.571+109%-1.131+315%-0.410+50%-0.455+67%
Usd Free Cash Flow To Equity Per Share--0.589-0.106+118%0.459+28%0.298+98%0.172+242%
Usd Market Cap2516088.000-78%4466056.2005241850.000-15%1367231.736+227%3236256.197+38%2771155.253+61%
Usd Price Per Share1.200-78%2.1302.500-15%0.652+227%1.268+68%1.137+87%
Usd Profit---4153506.000-1838273.500-56%-1222198.750-71%-937582.200-77%-1718568.233-59%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--1.9530.383+410%-0.073+104%0.438+346%0.084+2238%
 EOD+2 -6MRQTTM+23 -10YOY+22 -115Y+23 -1110Y+26 -8

3.3 Fundamental Score

Let's check the fundamental score of Bone Biologics Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.151
Price to Book Ratio (EOD)Between0-10.663
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than113.045
Current Ratio (MRQ)Greater than114.871
Debt to Asset Ratio (MRQ)Less than10.067
Debt to Equity Ratio (MRQ)Less than10.072
Return on Equity (MRQ)Greater than0.15-1.095
Return on Assets (MRQ)Greater than0.05-1.022
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Bone Biologics Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.916
Ma 20Greater thanMa 501.256
Ma 50Greater thanMa 1001.556
Ma 100Greater thanMa 2001.577
OpenGreater thanClose1.210
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Bone Biologics Corp

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Fundamental data was last updated by Penke on 2024-11-19 14:38:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Bone Biologics Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Bone Biologics Corp to the Medical Devices industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Bone Biologics Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ--6.4%+6.4%
TTM--15.2%+15.2%
YOY--15.4%+15.4%
5Y--18.1%+18.1%
10Y--22.9%+22.9%
4.3.1.2. Return on Assets

Shows how efficient Bone Biologics Corp is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bone Biologics Corp to the Medical Devices industry mean.
  • -102.2% Return on Assets means that Bone Biologics Corp generated $-1.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Bone Biologics Corp:

  • The MRQ is -102.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -47.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-102.2%TTM-47.7%-54.5%
TTM-47.7%YOY-22.1%-25.5%
TTM-47.7%5Y-4,610.7%+4,563.0%
5Y-4,610.7%10Y-6,724.4%+2,113.7%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-102.2%-2.1%-100.1%
TTM-47.7%-3.2%-44.5%
YOY-22.1%-4.0%-18.1%
5Y-4,610.7%-3.1%-4,607.6%
10Y-6,724.4%-4.1%-6,720.3%
4.3.1.3. Return on Equity

Shows how efficient Bone Biologics Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bone Biologics Corp to the Medical Devices industry mean.
  • -109.5% Return on Equity means Bone Biologics Corp generated $-1.10 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Bone Biologics Corp:

  • The MRQ is -109.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -53.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-109.5%TTM-53.3%-56.2%
TTM-53.3%YOY-46.0%-7.3%
TTM-53.3%5Y-22.4%-31.0%
5Y-22.4%10Y-11.2%-11.2%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-109.5%-2.4%-107.1%
TTM-53.3%-3.9%-49.4%
YOY-46.0%-4.5%-41.5%
5Y-22.4%-4.3%-18.1%
10Y-11.2%-5.6%-5.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Bone Biologics Corp.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Bone Biologics Corp is operating .

  • Measures how much profit Bone Biologics Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bone Biologics Corp to the Medical Devices industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Bone Biologics Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ--12.9%+12.9%
TTM--18.2%+18.2%
YOY--13.9%+13.9%
5Y--16.3%+16.3%
10Y--22.1%+22.1%
4.3.2.2. Operating Ratio

Measures how efficient Bone Biologics Corp is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Bone Biologics Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.254-1.254
TTM-1.324-1.324
YOY-1.326-1.326
5Y-1.373-1.373
10Y-1.314-1.314
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Bone Biologics Corp.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Bone Biologics Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 14.87 means the company has $14.87 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Bone Biologics Corp:

  • The MRQ is 14.871. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.479. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ14.871TTM13.479+1.393
TTM13.479YOY3.295+10.184
TTM13.4795Y16.578-3.099
5Y16.57810Y12.616+3.962
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ14.8712.550+12.321
TTM13.4792.691+10.788
YOY3.2952.922+0.373
5Y16.5783.415+13.163
10Y12.6163.527+9.089
4.4.3.2. Quick Ratio

Measures if Bone Biologics Corp is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bone Biologics Corp to the Medical Devices industry mean.
  • A Quick Ratio of 13.04 means the company can pay off $13.04 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Bone Biologics Corp:

  • The MRQ is 13.045. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.720. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ13.045TTM11.720+1.324
TTM11.720YOY3.031+8.690
TTM11.7205Y15.765-4.045
5Y15.76510Y10.938+4.827
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ13.0451.455+11.590
TTM11.7201.674+10.046
YOY3.0311.875+1.156
5Y15.7652.330+13.435
10Y10.9382.555+8.383
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Bone Biologics Corp.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Bone Biologics Corp assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bone Biologics Corp to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.07 means that Bone Biologics Corp assets are financed with 6.7% credit (debt) and the remaining percentage (100% - 6.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Bone Biologics Corp:

  • The MRQ is 0.067. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.105. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.067TTM0.105-0.038
TTM0.105YOY0.346-0.240
TTM0.1055Y1,373.110-1,373.004
5Y1,373.11010Y692.030+681.080
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0670.407-0.340
TTM0.1050.397-0.292
YOY0.3460.360-0.014
5Y1,373.1100.433+1,372.677
10Y692.0300.457+691.573
4.5.4.2. Debt to Equity Ratio

Measures if Bone Biologics Corp is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bone Biologics Corp to the Medical Devices industry mean.
  • A Debt to Equity ratio of 7.2% means that company has $0.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Bone Biologics Corp:

  • The MRQ is 0.072. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.125. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.072TTM0.125-0.053
TTM0.125YOY0.632-0.506
TTM0.1255Y0.162-0.037
5Y0.16210Y0.081+0.081
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0720.552-0.480
TTM0.1250.596-0.471
YOY0.6320.525+0.107
5Y0.1620.630-0.468
10Y0.0810.711-0.630
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Bone Biologics Corp generates.

  • Above 15 is considered overpriced but always compare Bone Biologics Corp to the Medical Devices industry mean.
  • A PE ratio of -0.27 means the investor is paying $-0.27 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Bone Biologics Corp:

  • The EOD is -0.151. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.269. Based on the earnings, the company is expensive. -2
  • The TTM is -0.976. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.151MRQ-0.269+0.117
MRQ-0.269TTM-0.976+0.707
TTM-0.976YOY-0.189-0.787
TTM-0.9765Y-1.464+0.488
5Y-1.46410Y-0.767-0.696
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-0.151-1.133+0.982
MRQ-0.269-1.442+1.173
TTM-0.976-2.000+1.024
YOY-0.189-2.111+1.922
5Y-1.464-1.922+0.458
10Y-0.767-2.040+1.273
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Bone Biologics Corp:

  • The EOD is -1.099. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.951. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.174. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.099MRQ-1.951+0.852
MRQ-1.951TTM-1.174-0.777
TTM-1.174YOY-0.127-1.047
TTM-1.1745Y-1.763+0.589
5Y-1.76310Y-1.155-0.608
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-1.099-1.367+0.268
MRQ-1.951-1.829-0.122
TTM-1.174-2.190+1.016
YOY-0.127-5.489+5.362
5Y-1.763-3.987+2.224
10Y-1.155-4.828+3.673
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Bone Biologics Corp is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 1.18 means the investor is paying $1.18 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Bone Biologics Corp:

  • The EOD is 0.663. Based on the equity, the company is cheap. +2
  • The MRQ is 1.178. Based on the equity, the company is underpriced. +1
  • The TTM is 1.633. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.663MRQ1.178-0.514
MRQ1.178TTM1.633-0.456
TTM1.633YOY0.297+1.336
TTM1.6335Y0.610+1.023
5Y0.61010Y0.124+0.486
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD0.6632.190-1.527
MRQ1.1782.142-0.964
TTM1.6332.358-0.725
YOY0.2973.005-2.708
5Y0.6104.156-3.546
10Y0.1244.646-4.522
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Bone Biologics Corp.

4.8.1. Institutions holding Bone Biologics Corp

Institutions are holding 4.587% of the shares of Bone Biologics Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30UBS Group AG1.6076033707331075517.8333
2024-06-30HRT FINANCIAL LLC0.83550.000117519175190
2024-06-30Tower Research Capital LLC0.27610.00015789153936.2118
2024-09-30McMahon Financial Advisors, LLC0.01920.000240300
2024-06-30Bank of America Corp0.00040990
2024-06-30Wells Fargo & Co000-4-100
2024-06-30Armistice Capital, LLC000-37000-100
2024-06-30Citadel Advisors Llc000-1417-100
Total 2.73880.000457427+13753+23.9%

4.9.2. Funds holding Bone Biologics Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Fidelity Extended Market Index0.4330.0001907883610.1432
Total 0.4330.00019078+836+9.2%

5.3. Insider Transactions

Insiders are holding 5.211% of the shares of Bone Biologics Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-13Deina H WalshBUY10005.12
2023-09-11Jeff FrelickBUY11875.52
2023-09-06Deina H WalshBUY8755.68
2023-08-31Jeff FrelickBUY9505.28
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets4,066
Total Liabilities273
Total Stockholder Equity3,792
 As reported
Total Liabilities 273
Total Stockholder Equity+ 3,792
Total Assets = 4,066

Assets

Total Assets4,066
Total Current Assets4,066
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 3,566
Other Current Assets 499
Total Current Assets  (as reported)4,066
Total Current Assets  (calculated)4,066
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities273
Long-term Liabilities0
Total Stockholder Equity3,792
Total Current Liabilities
Other Current Liabilities 273
Total Current Liabilities  (as reported)273
Total Current Liabilities  (calculated)273
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock2
Retained Earnings -83,500
Other Stockholders Equity 87,290
Total Stockholder Equity (as reported)3,792
Total Stockholder Equity (calculated)3,792
+/-0
Other
Cash and Short Term Investments 3,566
Common Stock Shares Outstanding 1,753
Liabilities and Stockholders Equity 4,066
Net Debt -3,566
Net Working Capital 3,792



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-06-302013-03-312012-12-312012-06-302012-03-312011-12-312011-06-302011-03-312010-12-312010-06-302010-03-312009-12-312009-06-302009-03-312008-12-312008-06-302008-03-31
> Total Assets 
-12
-22
-24
0
0
-40
0
0
0
0
0
0
0
0
-6
0
0
0
0
0
0
4
3
4
3
2,080
4,622
2,635
1,072
973
1,968
1,140
1,941
796
796
378
2,350
1,041
814
266
249
31
7
1
2
0
7
4
52
6,675
6,094
5,659
5,201
8,495
6,784
7,623
4,976
3,738
3,840
3,193
4,066
4,0663,1933,8403,7384,9767,6236,7848,4955,2015,6596,0946,67552470217312492668141,0412,3503787967961,9411,1401,9689731,0722,6354,6222,0803434000000-600000000-4000-24-22-12
   > Total Current Assets 
-12
-22
-24
0
0
-40
0
0
0
0
0
0
0
0
-6
0
0
0
0
0
0
4
3
4
3
2,074
4,622
2,634
1,072
973
1,968
1,140
1,940
796
796
378
2,350
1,041
814
266
249
31
7
1
2
0
7
4
52
6,675
6,094
5,659
5,201
8,495
6,784
7,623
4,976
3,738
3,840
3,193
4,066
4,0663,1933,8403,7384,9767,6236,7848,4955,2015,6596,0946,67552470217312492668141,0412,3503787967961,9401,1401,9689731,0722,6344,6222,0743434000000-600000000-4000-24-22-12
       Cash And Cash Equivalents 
-12
-22
-24
0
0
-40
0
0
0
0
0
0
0
0
-6
0
0
0
0
0
0
3
2
3
2
1,115
4,221
2,194
688
620
1,612
783
1,622
690
690
305
2,294
955
726
176
202
24
2
0
2
0
2
4
3
6,675
5,815
5,455
5,059
7,538
6,188
7,008
4,453
3,027
3,228
2,332
3,566
3,5662,3323,2283,0274,4537,0086,1887,5385,0595,4555,8156,6753420202242021767269552,2943056906901,6227831,6126206882,1944,2211,1152323000000-600000000-4000-24-22-12
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
340
301
301
301
272
272
272
272
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
580
0
0
0
329
329
0
0
00329329000580000000000000000000002722722722723013013013400000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
86
100
139
83
81
83
85
46
105
105
73
56
85
88
90
48
7
0
0
0
0
5
0
49
0
279
204
142
957
595
615
524
711
612
861
499
49986161271152461559595714220427904905000074890888556731051054685838183139100861111000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000060000000000000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000060000000000000000000000000
       Other Assets 
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
0
52
0
279
204
142
957
595
615
524
0
0
0
0
0000524615595957142204279052050000000000000000000000000000000000000000000100
> Total Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
0
0
5
8
8
5
6
7,761
7,634
7,950
8,123
9,607
10,238
11,390
12,845
9,191
9,191
9,834
9,525
9,639
10,786
11,122
11,631
11,898
12,471
12,846
13,241
13,692
12,471
14,620
15,178
100
55
71
799
2,548
4,011
1,930
1,183
831
165
285
273
2732851658311,1831,9304,0112,548799715510015,17814,62012,47113,69213,24112,84612,47111,89811,63111,12210,7869,6399,5259,8349,1919,19112,84511,39010,2389,6078,1237,9507,6347,7616588500600000000000000000
   > Total Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
0
0
5
4
4
0
0
2,145
2,307
2,305
2,159
3,325
3,637
4,506
5,643
962
962
1,271
525
9,639
10,786
11,122
11,631
578
12,471
12,846
13,241
13,692
12,471
14,620
15,178
100
55
71
799
2,548
4,011
1,930
1,183
831
165
285
273
2732851658311,1831,9304,0112,548799715510015,17814,62012,47113,69213,24112,84612,47157811,63111,12210,7869,6395251,2719629625,6434,5063,6373,3252,1592,3052,3072,1450044500600000000000000000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
0
0
3
4
4
0
0
0
0
0
0
1,200
1,564
2,109
2,888
8,230
2,109
600
0
9,000
9,700
10,700
11,200
0
0
0
0
0
11,448
12,491
12,768
0
0
0
0
784
0
0
0
0
0
0
0
0000000784000012,76812,49111,4480000011,20010,7009,7009,00006002,1098,2302,8882,1091,5641,20000000044300400000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,200
1,564
8,993
10,090
8,230
8,396
600
0
9,000
9,700
10,700
11,200
0
11,448
11,525
11,600
11,723
11,922
12,491
12,768
0
0
0
0
0
0
0
0
0
0
0
0
00000000000012,76812,49111,92211,72311,60011,52511,448011,20010,7009,7009,00006008,3968,23010,0908,9931,5641,20000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
187
283
273
336
227
73
114
225
217
217
260
65
125
518
178
138
43
213
249
400
465
213
84
70
100
55
71
799
888
2,279
1,689
1,103
361
146
232
0
02321463611,1031,6892,279888799715510070842134654002492134313817851812565260217217225114732273362732831870000000000000000000000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
2
0
0
0
0
1,958
2,024
2,032
1,823
1,823
1,823
1,823
1,823
47
745
411
459
514
568
243
294
536
94
94
0
0
810
2,045
2,339
0
55
71
0
1,659
1,732
241
81
471
18
8
273
273818471812411,7321,6590715502,3392,045810009494536294243568514459411745471,8231,8231,8231,8231,8232,0322,0241,9580000200200000000000000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
5
5
5,616
5,327
5,646
5,964
6,282
6,601
6,884
7,202
0
8,230
8,563
9,000
0
0
0
0
11,320
0
0
0
0
2,273
2,129
2,410
0
0
71
799
888
0
0
0
0
0
0
0
000000088879971002,4102,1292,273000011,32000009,0008,5638,23007,2026,8846,6016,2825,9645,6465,3275,6165544000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,230
8,396
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000008,3968,230000000000000000000000000000000000
> Total Stockholder Equity
0
0
-16
0
0
0
0
0
0
0
0
0
0
0
-36
-5
-39
-6
-6
-45
-4
-4
-5
-1
-2
-5,681
-3,012
-5,316
-7,050
-8,634
-8,270
-10,250
-10,904
-8,396
-8,396
-9,456
-7,174
-8,598
-9,972
-10,855
-11,382
-11,868
-12,465
-12,845
-13,239
-13,692
-12,465
-14,616
-15,125
6,575
6,039
5,588
4,402
5,947
2,772
5,693
3,793
2,906
3,675
2,909
3,792
3,7922,9093,6752,9063,7935,6932,7725,9474,4025,5886,0396,575-15,125-14,616-12,465-13,692-13,239-12,845-12,465-11,868-11,382-10,855-9,972-8,598-7,174-9,456-8,396-8,396-10,904-10,250-8,270-8,634-7,050-5,316-3,012-5,681-2-1-5-4-4-45-6-6-39-5-3600000000000-1600
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
5
0
5
5
5
0
0
0
0
0
0
0
0
32
38
39
39
39
39
39
39
43
43
4
8
26
28
30
31
31
31
31
31
31
31
31
12
10
10
10
10
15
17
3
3
1
1
1
2
21113317151010101012313131313131313130282684434339393939393938320000000055505000000000000
   Retained Earnings Total Equity0000000000000-69,789-69,2970000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-5
0
0
-6
0
0
0
0
0
0
-4
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000002000000000-4000000-600-5000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
55,142
55,142
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000055,14255,1420000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
25
44
45
46
48
48
50
52
52
55
52
59
20
58
20
2
69
25
7
8
9
14
16
20,206
29,843
32,338
34,976
38,271
41,709
38,865
40,738
1,823
50,746
52,441
54,962
54,991
55,022
55,062
55,096
55,142
0
0
0
0
55,142
55,142
55,160
77,041
77,194
77,212
77,245
77,892
78,426
83,129
83,149
83,815
85,449
85,466
87,290
87,29085,46685,44983,81583,14983,12978,42677,89277,24577,21277,19477,04155,16055,14255,142000055,14255,09655,06255,02254,99154,96252,44150,7461,82340,73838,86541,70938,27134,97632,33829,84320,20616149872569220582059525552525048484645442500



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.